ArticlePloS one2012
Mucosal immunization with live attenuated Francisella novicida U112ΔiglB protects against pulmonary F. tularensis SCHU S4 in the Fischer 344 rat model.
Article in PloS one, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 22 citations in OpenAlex.
- Marmosets as models of infectious diseases.Frontiers in cellular and infection microbiology · 2024Review
- Secretory System Components as Potential Prophylactic Targets for Bacterial Pathogens.Biomolecules · 2021Review
- Protective effects of the Francisella tularensis ΔpdpC mutant against its virulent parental strain SCHU P9 in Cynomolgus macaques.Scientific reports · 2019Article
- Lipoxin A4 receptor agonist BML-111 induces autophagy in alveolar macrophages and protects from acute lung injury by activating MAPK signaling.Respiratory research · 2018Article
- Microbial co-infection alters macrophage polarization, phagosomal escape, and microbial killing.Innate immunity · 2018Article
- An O-Antigen Glycoconjugate Vaccine Produced Using Protein Glycan Coupling Technology Is Protective in an Inhalational Rat Model of Tularemia.Journal of immunology research · 2018Article
- Live Attenuated Tularemia Vaccines for Protection Against Respiratory Challenge With VirulentFrontiers in cellular and infection microbiology · 2018Review
- Adaptive Immunity toFrontiers in cellular and infection microbiology · 2018Review
- Intratracheal Inoculation of Fischer 344 Rats with Francisella tularensis.Journal of visualized experiments : JoVE · 2017Article
- Article
- Comparison of virulence of Francisella tularensis ssp. holarctica genotypes B.12 and B.FTNF002-00.BMC veterinary research · 2017Article
- Detection of Signal Regulatory Protein α inFrontiers in immunology · 2017Article
- F. novicida-Infected A. castellanii Does Not Enhance Bacterial Virulence in Mice.Frontiers in cellular and infection microbiology · 2016Article
- Article
- Characterization of Francisella tularensis Schu S4 defined mutants as live-attenuated vaccine candidates.Pathogens and disease · 2015Article
- Live attenuated Francisella novicida vaccine protects against Francisella tularensis pulmonary challenge in rats and non-human primates.PLoS pathogens · 2014Article
- Article
- Tularemia vaccine development: paralysis or progress?Vaccine (Auckland, N.Z.)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
Abstract
The need for an efficacious vaccine against Francisella tularensis is a consequence of its low infectious dose and high mortality rate if left untreated. This study sought to characterize a live attenuated subspecies novicida-based vaccine strain (U112ΔiglB) in an established second rodent model of pulmonary tularemia, namely the Fischer 344 rat using two distinct routes of vaccination (intratracheal [i.t.] and oral). Attenuation was verified by comparing replication of U112ΔiglB with wild type parental strain U112 in F344 primary alveolar macrophages. U112ΔiglB exhibited an LD(50)>10(7) CFU compared to the wild type (LD(50) = 5 × 10(6) CFU i.t.). Immunization with 10(7) CFU U112ΔiglB by i.t. and oral routes induced antigen-specific IFN-γ and potent humoral responses both systemically (IgG2a>IgG1 in serum) and at the site of mucosal vaccination (respiratory/intestinal compartment). Importantly, vaccination with U112ΔiglB by either i.t. or oral routes provided equivalent levels of protection (50% survival) in F344 rats against a subsequent pulmonary challenge with ~25 LD(50) (1.25 × 10(4) CFU) of the highly human virulent strain SCHU S4. Collectively, these results provide further evidence on the utility of a mucosal vaccination platform with a defined subsp. novicida U112ΔiglB vaccine strain in conferring protective immunity against pulmonary tularemia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.